Related Experiment Video
Updated: Aug 5, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Topical ciclosporin in the treatment of ocular surface disorders
1The Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287-9238, USA.
Abstract:
Mounting evidence suggests that inflammation is the key factor in the pathogenesis of various ocular surface diseases, with a complex interplay of genetic, environmental, and psychosocial factors. Management of these conditions is often challenging. Topical corticosteroids, with their associated side effects, are the mainstay of current treatments for patients with vision threatening disease. Ciclosporin A is an immunomodulator that specifically inhibits T lymphocyte proliferation. Recently, a topical ciclosporin preparation was approved by the US Food and Drug Administration and became available for use in ophthalmology. Given the increasing use of ciclosporin eye drops, the goal of this article is to provide the reader with an overview of the well established uses of ciclosporin and to help refine the questions that should be addressed by future investigations.
Insights
Inflammation drives ocular surface diseases. Topical ciclosporin, an immunomodulator, offers a new treatment option, prompting a review of its established uses and future research directions.
Area of Science:
- Ophthalmology
- Immunology
- Inflammation
Background:
- Inflammation is central to ocular surface disease pathogenesis.
- Current treatments like topical corticosteroids have side effects.
- Ciclosporin A is an immunomodulator inhibiting T lymphocyte proliferation.
Purpose of the Study:
- Provide an overview of established ciclosporin uses in ophthalmology.
- Discuss the role of ciclosporin in ocular surface diseases.
- Identify future research questions regarding topical ciclosporin.
Main Methods:
- Literature review of ciclosporin A in ocular surface diseases.
- Analysis of clinical data and research on topical ciclosporin preparations.
- Synthesis of information on immunomodulatory effects and therapeutic applications.
Main Results:
- Topical ciclosporin A is now FDA-approved for ophthalmic use.
- Ciclosporin A specifically targets T lymphocyte proliferation.
- Established uses and emerging applications in managing ocular inflammation.
Conclusions:
- Topical ciclosporin represents a significant advancement in treating ocular surface diseases.
- Further research is needed to fully elucidate its long-term efficacy and safety profile.
- Understanding ciclosporin's role is crucial for managing complex inflammatory eye conditions.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Ophthalmic Drug Delivery Systems
Microbiome of the Eye

